Canadian diagnostics firm MedMira has obtained the CE mark for its Vyra COVID-19 Antigen Test.
The test has been designed to detect the SARS-CoV-2 virus in the swab samples.
MedMira has developed the rapid antigen test using its patented Rapid Vertical Flow (RVF) technology.
This test expands the current Covid-19 product family and addresses the need for a quick, reliable, and easy-to-use testing solution.
The test is designed to be non-invasive and user-friendly to make it more suitable for any settings.
The Vyra COVID-19 Antigen Test is currently available in Europe as well as in countries that accept the CE mark.
MedMira CEO Hermes Chan said: “Whereas VYRA COVID-19 provides a high-quality single antigen test for the detection of SARS-CoV-2 designed for customers who are worried about a Covid-19 infection, our upcoming VYRA CoV2Flu Antigen Test will further complement our product offering to customers who wish to have a result for Covid-19 or Flu A or Flu B immediately.
“With the increasing infection rates during the next few months and the need for quality rapid testing solutions, MedMira’s VYRA Covid-19 is the fastest and most reliable answer.”
In the coming weeks, the diagnostics company expects to receive a CE mark for the REVEALCOVID-19 Nab-Y Neutralising Antibody Test and VYRA CoV2Flu.
Upon receipt of the CE mark, MedMira will be able to provide a complete set of Covid-19 related products to its distribution partners.
In February, the company received the CE mark for its REVEALCOVID-19 PLUS Total Antibody Test, which has been designed to identify the presence of total antibodies.
